Virus warning for Merck’s $20,000 drug-coated asthma pill
On Tuesday, after a cost-benefit analysis on Merck’s drug-coated asthma drug was completed, analysts and investors were quick to pour cold water on the company’s hopes for a bright future in cancer and vaccines….